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The  novel  isoxazoline  ectoparasiticide,  sarolaner,  was  identiﬁed  during  a  lead optimization  program  for
an orally-active  compound  with  efﬁcacy  against  ﬂeas  and  ticks  on  dogs.  The  aim  of the  discovery  pro-
gram  was to identify  a novel  isoxazoline  speciﬁcally  for use in  companion  animals,  beginning  with  de
novo  synthesis  in  the  Zoetis  research  laboratories.  The  sarolaner  molecule  has  unique  structural  features
important  for  its potency  and pharmacokinetic  (PK)  properties,  including  spiroazetidine  and  sulfone  moi-
eties. The  ﬂea  and  tick  activity  resides  in  the  chirally  pure  S-enantiomer,  which  was  puriﬁed  to  alleviate
potential  off-target  effects  from  the  inactive  enantiomer.  The  mechanism  of action  was  established  in
electrophysiology  assays  using  CHO-K1  cell  lines  stably  expressing  cat  ﬂea (Ctenocephalides  felis)  RDL
(resistance-to-dieldrin)  genes  for  assessment  of GABA-gated  chloride  channel  (GABACls)  pharmacology.
As  expected,  sarolaner  inhibited  GABA-elicited  currents  at both  susceptible  (CfRDL-A285)  and  resistant
(CfRDL-S285)  ﬂea GABACls  with  similar  potency.  Initial  whole  organism  screening  was  conducted  in  vitro
using  a blood  feeding  assay  against  C.  felis.  Compounds  which  demonstrated  robust activity  in the ﬂea  feed
assay were  subsequently  tested  in  an in  vitro  ingestion  assay  against  the  soft  tick,  Ornithodoros  turicata.
Efﬁcacious  compounds  which  were  conﬁrmed  safe in  rodents  at doses  up  to  30 mg/kg  were  progressed
to  safety,  PK  and  efﬁcacy  studies  in  dogs.  In  vitro  sarolaner  demonstrated  an LC80 of  0.3  g/mL  against  C.
felis  and  an  LC100 of 0.003  g/mL against  O.  turicata.  In  a head-to-head  comparative  in vitro  assay  with
both  afoxolaner  and  ﬂuralaner,  sarolaner  demonstrated  superior  ﬂea  and  tick  potency.  In exploratory
safety  studies  in dogs,  sarolaner  demonstrated  safety  in  dogs  ≥ 8 weeks  of age  upon  repeated  monthly
dosing  at  up  to  20 mg/kg.  Sarolaner  was  rapidly  and well  absorbed  following  oral  dosing.  Time to  max-
imum  plasma  concentration  occurred  within  the  ﬁrst  day  post-dose.  Bioavailability  for sarolaner  was
calculated  at >85%  and  the  compound  was  highly  protein  bound  (>99.9%).  The half-life  for  sarolaner  was
calculated  at  11–12  days.  Sarolaner  plasma  concentrations  indicated  dose  proportionality  over  the  range
1.25–5  mg/kg,  and  these  same  doses  provided  robust  efﬁcacy  (> 99%)  for  ≥35  days  against  both  ﬂeas  (C.
felis)  and  multiple  species  of ticks  (Rhipicephalus  sanguineus,  Ixodes  ricinus  and  Dermacentor  reticulatus)
after  oral  administration  to dogs.  As a  result  of these  exploratory  investigations,  sarolaner  was  progressed
for  development  as  an  oral  monthly  dose  for  treatment  and  control  of  ﬂeas  and ticks  on dogs.
©  2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
In spite of an abundance of parasiticides available to protect
ogs and cats from ectoparasites, the market for novel, more effec-
ive and more convenient products continue to grow. Isoxazolines
re a potent new class of ectoparasiticide for companion animals.
∗ Corresponding author at: Zoetis, 333 Portage Street, Kalamazoo, MI  49007, USA.
E-mail addresses: tom.mctier@zoetis.com, trueson1@comcast.net (T.L. McTier).
ttp://dx.doi.org/10.1016/j.vetpar.2016.02.019
304-4017/© 2016 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
These compounds have demonstrated remarkable activity against
the most common parasites of dogs, ﬂeas and ticks, via the oral
route of administration. This has been a major breakthrough in par-
asite control, particularly for ticks, as the best previous acaricides
have been topically administered products. This new isoxazoline
class of parasiticide also has advantages over the ﬁrst generation
of oral parasiticides available to veterinarians, which had limited
ability to effectively kill both ﬂeas and ticks on dogs (Beugnet and
Franc, 2012). Fast and consistent efﬁcacy for the full dosing period
against ﬂeas and multiple species of ticks is an important attribute
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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mig. 1. Structure of sarolaner: 1) phenyl head group, 2) isoxazoline core, 3) spiroaze-
idinebenzofuran moiety and 4) methylsulfonylethanone tail.
f effective ectoparasiticides, both as a means to improve basic par-
site control and to reduce the potential for pathogen transmission.
roducts with a faster onset of action will help achieve both these
ims.
The mechanism of action (MOA) of the isoxazoline class of com-
ounds is well documented. Previous reports from the literature
ave demonstrated that the isoxazolines exhibit antiparasitic activ-
ty through speciﬁc blockade of insect GABA- and glutamate-gated
hloride channels (Garcia-Reynaga et al., 2013; Gassel et al., 2014;
zoe et al., 2010). The in vivo efﬁcacy of several of these com-
ounds (afoxolaner and ﬂuralaner) have been previously described
n numerous publications (Hunter et al., 2014; Rohdich et al., 2014;
hoop et al., 2014; Wengenmayer et al., 2014).
This paper describes the compound attributes, in vitro screening
trategy, initial in vivo ectoparasiticidal activity, pharmacology and
echanism of action (MOA) and basic pharmacokinetic (PK) proﬁle
f the novel isoxazoline, sarolaner. Sarolaner was designed in the
esearch laboratories at Zoetis and is the product of an intensive
ffort to discover and develop a novel isoxazoline speciﬁcally for
se in companion animals.
. Materials and methods
.1. Compound background and details
Sarolaner (1-(5′-((5S)-5-(3,5-dichloro-4-ﬂuorophenyl)-5-
triﬂuoromethyl)-4,5-dihydroisoxazol-3-yl)-3′-H-spiro(azetidine-
,1′-(2) benzofuran)-1-yl)-2-(methylsulfonyl) ethanone) was
iscovered during a 2-year lead optimization program. Over
000 isoxazoline compounds were prepared and tested to build
n understanding of the structure activity relationships of the
soxazoline class that led to the selection of sarolaner as the best
olecule for advancement as a candidate for product development.
Fig. 2. Structures of otasitology 222 (2016) 3–11
The molecule’s structure can be described as four connected sub-
units; a substituted phenyl ring head group, the isoxazoline core,
a spiroazetidinebenzofuran moiety and a methylsulfonylethanone
tail (Fig. 1). The molecule was optimized for broad-spectrum
ectoparasiticidal potency, pharmacokinetics and safety in the
dog as follows. The addition of a 4-substituted ﬂuorine to a
3,5-dichlorophenyl head unit provided superior tick potency com-
pared to any 4-hydrido-3,5-substituted patterns. The isoxazoline
was prepared as a single S-enantiomer due to all of the activity
residing in this chiral conformation; the R-enantiomer provided
no potency against ﬂeas or ticks. Mindful of enhancing safety in
canine patients, selecting the chirally pure form minimized poten-
tial off-target effects that could result from the incorporation of
the inactive enantiomer. The spiroazetidinebenzofuran moiety is a
unique structure, previously undescribed in the parasitology liter-
ature, providing rigidity, potency and novelty to the molecule. The
ﬁnal piece of optimization, yielded the methylsulfonylethanone
tail, increasing the polar surface area of the molecule and max-
imizing the pharmacokinetic exposure to target the rapid kill of
ﬂeas and ticks.
Afoxolaner and ﬂuralaner, which were originally both discov-
ered in the agrochemical ﬁeld, are presented below for reference
(Fig. 2).
2.2. Evaluation strategy
Preliminary efﬁcacy screening was conducted in vitro against
the cat ﬂea, Ctenocephalides felis felis, with active hits subsequently
screened against the soft tick, Ornithodoros turicata. Once initial efﬁ-
cacy had been proﬁled in vitro, the safety of selected compounds
was assessed in a mouse symptomatology model and those com-
pounds with an acceptable rodent safety proﬁle were progressed
to target animal toleration, pharmacokinetics and efﬁcacy studies
in the dog.
For all studies involving animals reported in this paper, animals
were handled with due regard to their welfare and all protocols
and procedures were reviewed by appropriate welfare authorities
and applicable procedures were conducted according to state and
national/international regulations.
2.3. In vitro screening—ﬂeas (Ctenocephalides felis)
Fleas were reared using an artiﬁcial dog apparatus to provide
regular supplies of an established laboratory strain of ﬂeas (C. felis
felis) not more than 48 h post-emergence. Approximately 30 adult
ﬂeas (mixed sex) were collected and aspirated into the feeding
chambers (modiﬁed 50 mL  centrifuge tube with a 300 mm mesh
top) and held at 25◦ C and 75% relative humidity (RH) until use.
Test compounds were made up as stock solutions in 0.5% dimethyl
her isoxazolines.
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ulphoxide (DMSO). Membrane feeding was carried out using a
at-bed incubator apparatus maintained at 37◦ C. Test solutions
ere added to 5 mL  of citrated bovine blood in a 50 mm diame-
er petri dish and sealed with a thin Nesco/Paraﬁlm membrane.
ontrol ﬂeas were fed on blood containing 0.5% (v/v) DMSO. Tubes
ith ﬂeas were placed in contact with membranes to allow ﬂeas
o feed through the mesh top. Fleas were allowed to feed for 2 h.
n removal from the feeding apparatus, ﬂeas were maintained at
5◦ C and 75% RH.
Efﬁcacy recordings (a subjective visual assessment of ﬂea via-
ility based on motility) were made at 2 and 24 h after initiation
f feeding. Screening assays were conducted in duplicate and com-
arative assays in triplicate. Each compound was  tested at half-log
ntervals, and endpoint data was recorded as LC80 (the lowest con-
entration to cause ≥ 80% mortality) in g/mL.
.4. In vitro screening—soft ticks (O. turicata)
Compounds demonstrating activity in the primary in vitro ﬂea
creens were then evaluated in an in vitro soft tick screen that used
 system similar to that described above for testing compounds
gainst ﬂeas. Five individual nymphal (N3-N4) O. turicata were
laced on top of the membrane covering a 50 mm petri dish con-
aining blood with test compound, and ticks were allowed to feed to
epletion (∼5–15 min). Assays were conducted in duplicate for ini-
ial screening and in triplicate for comparative assays. Ticks were
emoved and placed in a separate container with sand and incu-
ated for 72 h at 25 ◦C and 75% RH. Ticks were observed at 24 and
2 h for paralysis/mortality. Endpoint results for subjective visual
ssessment of organism viability were recorded as EC50 (the lowest
oncentration to cause ≥50% morbidity/mortality) and LC100 (the
owest concentration to cause 100% mortality) in g/mL.
.5. Safety screening
.5.1. Mouse symptomatology
Compounds that met  in vitro efﬁcacy potency targets were
elected for initial toxicity screening in mice. Symptomatology was
valuated in mice (n = 3 per compound), administering compounds
y oral gavage using aqueous micelle formulations. Visual obser-
ations for adverse effects were made at 0, 0.25, 0.5, 1, 2, 4 and 6 h
ost-dose. Observations included, but were not limited to, body
osture, hyper/hypo activity, grip strength, convulsions and ptosis.
ompounds were dosed up to 30 mg/kg body weight. Compounds
hat passed safety screening in mice were progressed to initial
afety screening in the dog.
.5.2. Target animal safety testing
Study 1: sarolaner was tested in adult dogs in an exploratory
argin of safety (MOS) repeat-dose study. Twenty-four adult Bea-
le dogs (12 males and 12 females) were allocated randomly to four
reatments of six dogs each: placebo or sarolaner at 2, 6 or 10 mg/kg.
reatments were blocked by pen location and day of study com-
letion. This study had a split-plot design, with sex as the whole
lot factor and treatment as the sub-plot factor. The compound
as formulated in capsules with excipients (microcrystalline cellu-
ose, sodium starch glycolate, sodium lauryl sulfate and magnesium
tearate) and delivered orally. Each treatment group was dosed
hree times at 28-day intervals. Dogs were fed an appropriate ration
f a commercial dry canine feed for the duration of the study. Water
as available ad libitum.
Observations included body weight, serum chemistry (includ-ng serum thyroxine, T4), hematology, coagulation, urinalysis, and a
ualitative estimate of food intake. Directed clinical and neurologic
xaminations were conducted by a veterinarian. Blood samples
ere collected and analyzed for pharmacokinetic assessment. Aasitology 222 (2016) 3–11 5
full post-mortem examination was conducted one week after the
third dose. This included macroscopic examination and collection
of selected organs. Microscopic evaluation was conducted by a
board-certiﬁed veterinary pathologist.
Study 2: an exploratory repeat dose tolerance study with
sarolaner in young dogs was conducted. Thirty-two 8-week-old
intact male and female beagle dogs were allocated randomly to
four treatments of 8 dogs each: placebo or sarolaner at 4, 12 or
20 mg/kg. Treatments were blocked by pen and day of study com-
pletion. Dogs were pair housed because of their young age. This
study had a split-plot design with sex as the whole plot factor and
treatment as the sub-plot factor. Each dog was dosed twice at a
28-day interval, followed by a complete post-mortem examination
one week after the second dose. The compound was  formulated and
delivered as in Study 1. Similar end point observations to those in
Study 1 were made for the dogs in Study 2. Dogs were fed an appro-
priate ration of a commercial dry canine feed for the duration of the
study. Water was  available ad libitum.
2.6. Pharmacokinetics
The pharmacokinetics of sarolaner were assessed in a parallel
design bioavailability study.
2.6.1. Animals
Purpose-bred Beagle dogs (male and female), at least 6 months
of age and weighing at least 10 kg were used in the study. Each
animal was  uniquely identiﬁed and was in good health at treat-
ment. Dogs were housed individually in accordance with accepted
laboratory animal care and use guidelines, and dogs were allowed
regular opportunity for exercise and social interaction. Dogs were
fed an appropriate ration of a commercial dry canine feed for the
duration of the study. Water was  available ad libitum.
2.6.2. Experimental design and methods
Dogs were acclimated to the study conditions for at least 15
days prior to treatment. The dogs were observed for general health
twice daily throughout the study. A physical exam was performed
on each dog by a veterinarian to determine health and suitability
prior to inclusion in the trial. Animals were fasted overnight prior to
dose administration, and fed at 4 h post dose. Dogs were randomly
allocated to 2 treatments of 12 dogs each (6 male/6 female). On
Study Day 0, dogs were administered study treatments: sarolaner
was dosed either as an intravenous solution, or as a compressed
tablet for oral administration. Intravenous doses were adminis-
tered at 2 mg/kg and oral doses were administered at 20 mg/dog.
Pharmacokinetic data was  dose normalized to 2 mg/kg, based on
the Day 0 body weights. Blood samples for pharmacokinetic analy-
sis were collected from all animals prior to dosing, and at multiple
time points post dose, through Day 56.
2.7. Pharmacology and mechanism of action (MOA)
Chinese Hamster Ovary (CHO-K1) cells stably expressing ﬂea (C.
felis) RDL (resistance-to-dieldrin) genes were generated to assess
GABA-gated chloride (GABACl) pharmacology of sarolaner. RDL
subunits of interest (including the alanine-to-serine dieldrin resis-
tance mutation) were codon optimized for CHO-K1 expression by
GeneART-Invitrogen (Carlsbad, CA) and subcloned into the mam-
malian expression vector pcDNA3.1(+) using introduced BamHI
and NotI restriction sites. The resulting constructs (CfRDL-A285,
CfRDL-S285) were introduced into CHO-K1 cells using FuGene
HD transfection reagent (Promega). CHO cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium + Glutamax (Invitrogen) sup-
plemented with 10% dialyzed fetal bovine serum (dFBS), 10 mM
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EPES, 1X Anti–Anti (Invitrogen) at 37 ◦C and 5% CO2. Trans-
ected cell lines were selected by the addition of 500 g/mL G418.
esistant colonies were apparent within 2 weeks of selection and
icked to individual wells of 24-well plates for assessment of func-
ion. Growth media was HAMS-F12 supplemented with GlutaMAX,
0% Fetal Bovine Serum, 1% Non-Essential Amino Acids, 1% Peni-
illin/Streptomycin along with G418 (800 g/mL) and hygromycin
 (300 g/mL) selection. Cells were maintained in a humidiﬁed
ncubator (37 ◦C/5% CO2) in T225 ﬂasks and expanded to 80–90%
onﬂuence prior to the experiment. For electrophysiology exper-
ments, a cell suspension of 3–4 × 106 cells/mL was prepared
mmediately prior to the studies.
Electrophysiology studies were conducted using the IonWorks
latform. Basic principles and operation of the IonWorks platform
ave been described by Schroeder et al. (2003). The external solu-
ion used in the experiments was a HEPES-buffered saline solution.
he composition of extracellular solution was (in mM):  137 NaCl, 4
Cl, 1.8CaCl2, 1.0 MgCl2, 10HEPES, pH adjusted to 7.4 with NaOH.
he internal solution used for the experiment was  (in mM):  100
Gluconate, 40 KCl, 3.2 MgCl2, 3.2 EGTA and 5HEPES; pH adjusted
o 7.25–7.30 with KOH. The antibiotic perforating agent used in
his experiment was amphotericin B added to the internal solution
t a concentration of 120 g/mL. All salts and antibiotic perforat-
ng agents were obtained from Sigma Aldrich, except KGluconate
hat was purchased from VWR. All recordings were made at room
emperature.
-Aminobutyric acid (GABA, A2129 Sigma Aldrich) was dis-
olved in water at a concentration of 100 mM and diluted
n external solution to a concentration of 1 mM for agonist
oncentration-response experiments and 300 M for antagonist
xperiments. An eight point, 3-fold serial dilution series was
repared from the 1 mM stock solution to a ﬁnal low assay con-
entration of 450 nM to evaluate agonist potency. An eight-point
oncentration series was constructed for each compound (n = 8
ells/test concentration) with a 3-fold dilution scheme. External
olution (99.5 L) was added to each well of the plate resulting
n an eight-point concentration-response series with a top ﬁnal
ssay concentration of 10 M and a low ﬁnal assay concentra-
ion of 4.6 nM.  In antagonist evaluations, test compounds were also
ncluded in the second addition along with EC80 of GABA.
After achieving voltage-clamp control, all cells were held at a
otential of −80 mV  for the duration of the experiment and sampled
t a frequency of 2–10 kHz. Fluidic additions were made simul-
aneously in all 384 wells using the integrated 384 well pipettor
n the IonWorks Barracuda. Each concentration of test compound
as added to 4–8 wells in each experiment for subsequent analy-
is. For agonist effects, test compounds were added at a volume of
5 L at 10 L/s. Recordings were sampled for a period of 1 s prior
o compound addition and 15 s following compound addition. For
ntagonist effects, test compounds were added and voltage clamp
ecordings were sampled as described above. Five minutes after
est compound addition, agonist was added at approximately EC80
oncentration for evaluation of inhibitory activity of the test com-
ound. Recordings were sampled for a period of 1 s prior to agonist
ddition and 10 s following agonist addition.
Voltage-clamp recordings from each of the 384 wells of the
atchPlate were evaluated for seal resistance, current amplitude
nd stability. Data from wells with seal resistances less than 20 M
uring the course of the experiment or with unstable baseline
urrents prior to or following ﬂuidic addition (assessed by visual
nspection of voltage-clamp traces) were eliminated from the data
nalysis.GABA produced concentration-dependent inward Cl− currents
nder the assay conditions. For wells passing the criterion above,
eak inward current was determined by subtracting baseline
urrent (average currents for a 50 ms  window 100 ms  beforeasitology 222 (2016) 3–11
compound addition) from maximum inward currents from a win-
dow for 4 s following compound addition. Concentration-response
data for peak inward current were ﬁt using non-linear regres-
sion analysis to determine EC50 and EC80 concentrations using
a sigmoidal dose-response equation (GraphPad version 5). The
approximate EC80 concentration of agonist was used in subsequent
experiments to evaluate test compound antagonist activity.
Percent inhibition of GABA-induced inward current was calcu-
lated for each concentration of test compound by comparing with
in-plate agonist controls by the following equation:
(AgonistEC80average − TestCompound)/(AgonistEC80average) × 100
Eight-point concentration-response curves were constructed
from pooled data and were ﬁt using non-linear regression anal-
ysis (GraphPad version 5) to determine IC50 concentrations using
a sigmoidal concentration-response relationship. For most curve
ﬁts, maximum block was constrained to 100% and minimum con-
strained to 0%.
2.8. Efﬁcacy evaluation in dogs
The in vivo efﬁcacy against ﬂeas and ticks was proﬁled in two
studies in dogs. The studies were conducted in accordance with
the World Association for the Advancement of Veterinary Parasitol-
ogy (WAAVP) guidelines for evaluating the efﬁcacy of parasiticides
for the treatment, prevention and control of ﬂea and tick infes-
tation on dogs and cats (Marchiondo et al., 2013). Masking was
assured through the separation of functions. All personnel conduct-
ing observations or animal care, or performing ﬂea infestations and
counts were masked to treatment allocation.
2.8.1. Animals
Adult (male and female), purpose-bred Beagles at least 8 months
of age and weighing greater than 20 kg were used in both studies.
Each dog was  individually identiﬁed, had not been treated with an
ectoparasiticide for at least 60 days and was  in good health at treat-
ment. Dogs were housed individually in indoor runs. Dogs were fed
an appropriate maintenance ration of a commercial dry canine feed
for the duration of the study. Water was available ad libitum.
2.8.2. Experimental design and methods
General methods. Day 0 for each study was the day dogs were
administered the study treatment. Dogs were acclimated to the
study conditions for at least 14 days prior to treatment. The dogs
were observed for general health at least once daily throughout
the studies. A physical exam was  performed on each dog by a vet-
erinarian to determine health and suitability prior to inclusion in
the trial. For infestations in Study 1, approximately 100 cat ﬂeas (C.
felis felis, 1:1 sex ratio) or approximately 50 ticks (∼1:1 sex ratio)
of each species to be assessed were applied directly to a site proxi-
mal  or adjacent to the shoulder blades and allowed to crawl into the
dog’s coat. In Study 2, dogs were sedated prior to tick infestation, to
reduce animal movement and enhance tick attachment. Forty-eight
hours after treatment and after each tick infestation and/or 24 h
after each ﬂea infestation, the dogs were examined and combed to
remove and count ﬂeas and ticks. All dogs were ﬁrst examined visu-
ally, and any ticks detected were removed using forceps. Ticks were
examined to determine their viability. Any tick able to move in a
coordinated manner was  considered live. The dogs were then thor-
oughly ﬂea combed to count and remove ﬂeas and any remaining
ticks. Commercial ﬁne-toothed ﬂea combs were used. Dogs were
systematically combed initially while standing starting from the
head, then proceeding caudally along the dorsum; then the sides
and ventral aspects were combed. Dogs were repeatedly combed
until no ﬂeas were recovered for about 5 min. Each animal was
examined for a minimum of 10 min. Fleas able to stand upright
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Table  1
Efﬁcacy of a representative sample of novel isoxazolines in in vitro screening assays with compounds fed in blood to ﬂeas (Ctenocephalides felis felis) and soft ticks (Ornithodoros
turicata)  (n = 2).
Compound ID Chemistry Structure Flea Feed (C. felis) LC80 (g/mL) Soft Tick Feed (O. turicata) LC100 (g/mL)
PF-06279149 Racemic >3 N.T.
PF-06272420 Racemic 3 0.1
PF-06279093 Racemic 1 0.1
PF-06377581 Racemic 1 0.1
PF-06450567 (Sarolaner) S-enantiomer 0.3 0.003
N.T. = not tested.
Table 2
Comparative in vitro efﬁcacy of isoxazolines in in vitro assays with compounds fed in blood to ﬂeas (Ctenocephalides felis felis) and soft ticks (Ornithodoros turicata) (n = 3).
Compound ID Chemistry Flea Feed (C. felis) LC80 (g/mL) Soft Tick Feed (O. turicata) LC100 (g/mL)
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nd/or move in a coordinated manner were considered live. Pro-
ective gloves and clothing were changed between dogs. Separate
ea combs were used for each animal.
Study 1. On Day-7, each dog was infested with Rhipicephalus
anguineus. On Day-5, the ticks on each dog were counted, dogs
ere ranked by descending tick count into blocks, and randomly
llocated within blocks to two treatment groups of eight dogs each.
n Day-2, the dogs were weighed and infested with R. sanguineus
nd Dermacentor reticulatus ticks. On Day-1, the dogs were infested
ith ﬂeas. On Day 0, each animal was treated via oral gavage at
.5 mL/kg body weight with either placebo control or sarolaner
olution (5 mg/mL) to provide a dose of 2.5 mg/kg. A tetragly-
ol/solutol solution base was used to formulate the sarolaner. Dogs
ere observed for general health and any reaction to treatment
pproximately 1, 3 and 6 h after treatment on Day 0, then once daily
or the remainder of the study. On Day 2, each dog was examined
nd combed to count and remove ﬂeas and ticks. Subsequently, all
nimals were infested with R. sanguineus and D. reticulatus on Days
, 12, 19, 25 and 33, and with ﬂeas on Days 6, 13, 20, 26 and 34. All
ogs were examined, combed and parasite counted on Days 7, 14,
1, 27 and 35.
Study 2. On Day-9, each dog was infested with Ixodes ricinus.
n Day-7, the ticks on each dog were counted, the dogs ranked by
escending tick count into eight blocks of four, and randomly allo-
ated within blocks to four treatment groups of eight dogs each.
n Day-2, the dogs were weighed and infested with I. ricinus ticks.
n Day 0, each animal was treated via oral gavage at 0.5 mL/kg
ody weight with either placebo control, sarolaner suspension
10 mg/mL) to provide a dose of 5 mg/kg, sarolaner suspension
5 mg/mL) to provide a dose of 2.5 mg/kg or sarolaner suspen-
ion (2.5 mg/mL) to provide a dose of 1.25 mg/kg. The suspensions
ere formulated in a carboxymethylcellulose/Tween-80 base with
ater. Dogs were observed for general health and any reaction to0.1
0.1
0.03
treatment approximately 1, 3 and 6 h after treatment on Day 0,
then once daily for the remainder of the study. On Day 2, each dog
was examined and combed to remove and count ticks (as described
above). Subsequently, all animals were infested with I. ricinus on
Days 5, 12, 19, 26, 33 and 55. All dogs were examined and combed
and live ticks were counted on Days 7, 14, 21, 28 and 57. Blood sam-
ples for pharmacokinetic assessment were collected at least weekly
for the duration of the study.
2.8.3. Data analysis
The individual dog was the experimental unit and the primary
endpoint was live ﬂea and/or tick count. Flea and tick counts were
transformed by the loge(count + 1) transformation prior to analy-
sis in order to stabilize the variance and normalize the data. Using
the PROC MIXED procedure (SAS 8.2, Cary NC), transformed counts
were analyzed in a mixed linear model for repeated measures.
The model included the ﬁxed effect of treatment, day of study and
the interaction between treatment and day of study. The random
effects included room, block within room, the interaction between
block and treatment within room (animal term) and error. In Stud-
ies 1 and 2, a priori contrasts were used to compare treatment
means to the control at the one-sided signiﬁcance level =0.05.
Testing was  two-sided at the signiﬁcance level =0.05. Percent efﬁ-
cacy, relative to the control group and based on arithmetic (and
geometric) means, was  calculated as follows:%Efﬁcacy = (Mean Control - Mean Treated)
Mean Control
× 100
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Table 3
GABACl channel pharmacology: GABA EC50 values and antagonist IC50 values.
Compound ID CfRDL-A285 CfRDL-S285
GABA (EC50, M)  68 ± 7.8 43 ± 2.9
Sarolaner (IC50, nM) 135 ± 33 136 ± 16
Afoxolaner (IC50, nM) 539 ± 74 412 ± 79
Dieldrin (IC50, nM) 6920 ± 992 >33,000+
Concentration-response curves represent mean ± standard error (S.E.) of 3–8 exper-
iments.
Fig. 4. GABA concentration-responses at homomeric C. felis (CfRDL-A285 and
CfRDL-S285) GABACls. Concentration-dependent activation of GABACls was
measured by voltage-clamp electrophysiology. Concentration–response curves rep-ig. 3. Least squares (LS) mean plasma concentrations (ng/mL) with 95% conﬁdence
ntervals, following intravenous or oral administration to dogs.
. Results
.1. In vitro screening for ﬂea and ticks
Sarolaner (PF-06450567) was identiﬁed as the most potent of
he isoxazolines tested in the in vitro screening system with a LC80
f 0.3 g/mL for ﬂeas and LC 100 of 0.003 g/mL for O. turicata soft
icks (Table 1). In addition sarolaner was proﬁled against other isox-
zolines, afoxolaner and ﬂuralaner, in a head-to-head comparison
nd was shown to be the most potent of the three compounds in
hese in vitro assays with a LC80 of 0.1 g/mL against ﬂeas and a
C100 of 0.03 g/mL against O. turicata ticks (Table 2). The minor
ifferences observed between sarolaner potency in these assays are
ithin the biological variability often observed with these assays.
he assays were conducted at different times and this underscores
he importance of conducting head-to-head assays when compar-
ng relative potencies of compounds in vitro.
.2. Safety screening
.2.1. Mouse symptomatology
Twenty isoxazoline compounds were assessed in mice as the
rimary in vivo safety screen. Sarolaner did not cause any adverse
eactions in mice at screening doses of 10 and 30 mg/kg.
.2.2. Target animal safety testing
Oral administration of 2, 6 and 10 mg/kg of sarolaner 3 times
t 28-day intervals to adult dogs and oral administration of 4,
2 and 20 mg/kg of sarolaner 2 times, at 28-day intervals to 8-
eek-old dogs was well-tolerated at all dose levels. No adverse
eactions associated with treatment were observed for any of the
arolaner-treated dogs. Toxicokinetic evaluation indicated dose
roportional systemic exposure for both adult and young dogs.
est article-related changes for clinical pathology, gross pathology,
rgan weight and histopathology parameters were minimal and
ot considered adverse or clinically relevant.
.3. Pharmacokinetics
Following administration of the intravenous dose at 2 mg/kg,
he least square (LS)-mean value for volume of distribution (Vdss)
as 2.81 L/kg bodyweight, and the LS-mean value for clear-
nce (CL) was 0.12 mL/min/kg bod weight. Sarolaner was  rapidly
nd well absorbed following oral dosing at 20 mg/dog (dose
ange 2.17–3.79 mg/kg) (Fig. 3). Oral pharmacokinetic parame-
ers Cmax and AUC0-∞ were dose normalized according to the
ollowing equation: (PK parameter)(2 mg/kg)/Actual dose admin-resent mean ± S.E. (bars) of 3–8 independent experiments.
istered. Bioavailability was determined by the ratio of AUC0-∞/Oral
dose: AUC0-∞/IV dose. LS mean tmax following oral administra-
tion to fasted dogs occurred within the ﬁrst day post dose, with
dose-normalized LS mean Cmax at 1100 ng/mL, and bioavailability
calculated at >85%. T1/2 for sarolaner was  calculated at 11–12 days.
3.4. Mechanism of action (MOA) and pharmacology
In voltage clamp electrophysiology studies with recombinant
CHO-K1 cell lines stably expressing RDL subunits from C. felis, GABA
induced strong inward currents and exhibited agonist responses
with EC50 of 68 M and 43 M at CfRDL-A285 and CfRDL-S285,
respectively (Table 3 and Fig. 4).
In functional assays with invertebrate GABACls, sarolaner failed
to activate the CfRDL-A285 or CfRDL-S285 as measured by voltage-
clamp electrophysiology (data not shown). However, consistent
with the published mechanism of action for this chemical class
(Gassel et al., 2014; Ozoe et al., 2010; Shoop et al., 2014), sarolaner
potently blocked GABA-induced currents with IC50 of 135 nM and
136 nM at CfRDL-A285 and CfRDL-S285 receptors, respectively
(Table 3 and Fig. 5A and B). For comparative purposes, afoxolaner
was evaluated for inhibitory activity and demonstrated 3–4 fold
weaker blockade of GABA-induced currents with IC50 of 539 nM
and 412 nM at CfRDL-A285 and CfRDL-S285 receptors, respectively
(Table 3 and Fig. 5A and B).
To conﬁrm the dieldrin resistance phenotype in CfRDL-S285,
dieldrin concentration-response curves were examined. Dieldrin
blocked GABA-induced currents in CfRDL-A285 with an IC50 of
6920 nM,  while demonstrating a signiﬁcant rightward shift in
potency at CfRDL-S285 with an IC50 of >33,000 nM.  (Table 3 and
Fig. 5C). These data are consistent with previous literature reports
demonstrating dieldrin functionality being sensitive to a single
amino acid substitution of alanine to serine at position 285 of the
CfRDL (Gassel et al., 2014), and therefore conﬁrmed the resistance
phenotype.
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Fig. 5. Inhibition of GABA-induced currents at homomeric C. felis (CfRDL-A285 and
CfRDL-S285) GABACls. Concentration-dependent inhibition of a ﬁxed concentra-
tion (approximate EC80 concentration) of GABA was measured by voltage-clamp
electrophysiology. (A) Sarolaner (closed squares) and afoxolaner (closed trian-
gles)  inhibition of GABA-induced currents in CfRDL-A285 GABACls. (B) Sarolaner
(open squares) and afoxolaner (open triangles) inhibition of GABA-induced
currents in CfRDL-S285 GABACls. (C) Dieldrin inhibition of GABA-induced cur-
rents in CfRDL-A285 (closed circles) and CfRDL-S285 (open circles) GABACls.
Concentration–response curves represent mean ± S.E. (bars) of 3–8 independent
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Table 4
Arithmetic (geometric) mean ﬂea (C. felis) counts for placebo control and sarolaner-
treated dogs and percent efﬁcacy relative to controls.
Count Day Placebo Control Sarolaner Solution 2.5 mg/kg (C. felis)
2 62.5 (59.8) 0.0* [100]
7  72.4 (71.2) 0.0* [100]
14  78.9 (77.8) 0.0* [100]
21  82.0 (80.1) 0.0* [100]
28  76.5 (75.3) 0.1* [99.9]
35  70.9 (69.4) 0.0* [100]
* Mean counts are signiﬁcantly different to control; P < 0.05. Percent efﬁcacy,
based on arithmetic means, is given in brackets []. 48-h post-treatment counts on
Day 2 and 24 h post-infestation counts on all other days.
Table 5
Arithmetic (geometric) mean tick (Rhipicephalus sanguineus and Dermacentor retic-
ulatus)  counts for placebo control and Sarolaner-treated dogs and percent efﬁcacy
relative to controls.
Count Day Placebo Control Sarolaner Solution (2.5 mg/kg)
R. sanguineus D. reticulatus R. sanguineus D. reticulatus
2 20.0 (19.3) 25.9 (24.3) 0.0* [100] 0.0* [100]
7  27.0 (26.0) 33.8 (33.1) 0.0* [100] 0.1* [99.6]
14  13.5 (12.7) 32.4 (31.9) 0.0* [100] 0.0* [100]
21  23.3 (22.3) 31.4 (31.0) 0.0* [100] 0.4 (0.3)* [98.8]
28  18.0 (17.1) 31.9 (31.2) 0.0* [100] 0.6* [98.0]
35  26.3 (25.4) 26.4 (25.7) 0.0* [100] 0.0* [100]
* Mean counts are signiﬁcantly different to control; P < 0.05. Percent efﬁcacy,
based on arithmetic means, is given in brackets []. 48-h counts on all days.
Table 6
Arithmetic (geometric) mean Ixodes ricinus counts for placebo control and sarolaner-
treated dogs and percent efﬁcacy relative to controls.
Count Day Placebo Control Sarolaner (mg/kg, suspension)
1.25 2.5 5.0
2 22.9 (22.5) 0.0* [100] 0.0* [100] 0.0* [100]
7  18.0 (17.6) 0.0* [100] 0.0* [100] 0.0* [100]
14  20.6 (20.5) 0.1* [99.4] 0.0* [100] 0.0* [100]
21  19.3 (18.8) 0.0* [100] 0.0* [100] 0.0* [100]
28  18.5 (18.3) 0.0* [100] 0.1* [99.3] 0.0* [100]
35  17.4 (17.0) 0.1* [99.3] 0.0* [100] 0.0* [100]
57  22.0 (21.8) 4.4* [80.1] 0.1* [99.4] 0.0* [100]
* Mean counts are signiﬁcantly different to control; P < 0.05. Percent efﬁcacy,xperiments.
.5. Dog efﬁcacy
Study 1. Placebo-treated animals maintained good ﬂea (mean
ange, 59.8–80.1) and tick infestations (mean range: R. san-
uineus, 12.7–26.0; D. reticulatus:  24.3–33.1) throughout the study
Tables 4–6 ). Live ﬂea and tick counts for all sarolaner groups were
igniﬁcantly lower than the placebo group (P ≤ 0.05) on all post-
reatment count days. Percentage reductions are reported based
n arithmetic mean calculations.
Sarolaner, administered in a solution formulation at 2.5 mg/kg,
rovided 100% reduction in live ﬂea counts 48 h after treatment of
he existing infestation, and ≥99.9% reduction in live ﬂea counts
hen evaluated 24 h after each weekly re-infestation for 35 days
Table 4).
Against R. sanguineus,  sarolaner (2.5 mg/kg, oral solution) was
00% efﬁcacious at 48 h after treatment and against subsequent
nfestations through Day 35 (Table 5). Similar efﬁcacy was  seenbased on arithmetic means, is given in brackets []. 48-h counts on all days.
against D. reticulatus,  with ≥ 98.0% efﬁcacy achieved for the entire
study period (Table 5).
Study 2. Placebo-treated animals maintained adequate tick
infestations of I. ricinus for the entire study period (Days-2–57),
with a geometric mean of 18–23 ticks per dog (Table 6). Live tick
counts for all of the sarolaner groups were signiﬁcantly lower than
those for the placebo group (P ≤ 0.05) on all post-treatment count
days. Percentage reductions are reported based on arithmetic mean
calculations.
Against an existing infestation of I. ricinus, sarolaner at all doses
provided 100% reduction in live tick counts at 48 h after treatment
(Table 6). The two highest doses, 5.0 and 2.5 mg/kg, provided >99.3%
reduction against subsequent re-infestations through Day 57. Per-
sistent efﬁcacy for the 1.25 mg/kg dose was  ≥99.3% for 35 days,
dropping to 80.1% on Day 57.
Maximum sarolaner plasma concentrations were most often
observed within the ﬁrst day post-dose (Fig. 6). Following Cmax,
plasma concentrations decreased over the two-month study
duration. Sarolaner plasma concentrations indicated dose propor-
tionality over the range 1.25–5 mg/kg.
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tig. 6. Mean sarolaner plasma proﬁles, with standard deviations, following admin-
stration to dogs in an oral suspension.
.6. Health observations
There were no adverse health events noted for any dogs in Stud-
es 1 and 2.
. Discussion
The discovery of the novel isoxazoline, sarolaner, was  the
esult of an intensive collaborative and multi-disciplinary research
rogram involving medicinal chemistry, in vitro and in vivo par-
sitology, pharmacology and metabolism and safety research
cientists at Zoetis. Sarolaner is a chirally pure molecule optimized
or potency, safety and pharmacokinetics in the dog.
Sarolaner emerged as the most potent of more than 3000 com-
ounds tested and was more potent than the currently marketed
soxazolines, afoxolaner and ﬂuralaner, in our in vitro parasite
creening systems. Similar in vitro parasite screening systems have
een reported previously for ﬂeas (Zakson-Aiken et al., 2001) and
ave been used to evaluate and screen other isoxazoline com-
ounds (Shoop et al., 2014). In our in vitro screening system, the
ea assay was used as a primary screening assay and the tick assay
o discriminate between the potencies of previously identiﬁed ﬂea
ctive molecules.
Sarolaner demonstrated oral safety in initial in vivo studies in
odents up to 30 mg/kg, the highest dose evaluated, and was  pro-
ressed to safety studies in dogs, where no adverse effects were
bserved in dogs ≥ 8 weeks of age with repeated monthly doses up
o 20 mg/kg.
Pharmacokinetics was used as one of the pillars in the screening
rogram to select sarolaner as the lead molecule for further pro-
ression. Sarolaner was rapidly and well absorbed following oral
osing at 20 mg/dog. Following oral administration to fasted dogs,
max occurred within the ﬁrst day post dose, with dose-normalized
2 mg/kg) LS mean Cmax at 1100 ng/mL, and bioavailability cal-
ulated at >85%. T1/2 for sarolaner was calculated at 11–12 days.
oses across the range of 1.25–5 mg/kg in an aqueous suspension
ppeared proportional, indicating linearity. These PK character-
stics made sarolaner an acceptable candidate molecule for oral
onthly dosing.
Previous literature has shown that the primary mechanism of
ction for the isoxazoline class is through inhibition of inverte-
rate ligand-gated chloride channels, speciﬁcally GABACls (Ozoe
t al., 2010). Sarolaner was evaluated for functional activity using
ecombinant CHO-K1 cell lines stably expressing RDL subunits from
. felis (CfRDL-A285 and CfRDL-S285). Voltage-clamp electrophys-
ology conﬁrmed that sarolaner potently blocked GABA-induced
urrents with IC50 values of 135 nM and 136 nM at CfRDL-A285
nd CfRDL-S285 receptors, respectively. Of particular interest, was
hat sarolaner exhibited similar potency in blocking GABA-inducedasitology 222 (2016) 3–11
currents in the resistant ﬂea allele containing an alanine-to-serine
mutation at position 285, which has been well established to con-
fer cylodiene resistance (ffrench-Constant et al., 2004; Bloomquist
et al., 1992; Gassel et al., 2014). By contrast, dieldrin showed potent
blockade of the susceptible CfRDL-A285 channel (IC50 of 6920 nM),
while demonstrating poor antagonism at the resistant CfRDL-S285
channel (IC50 > 3300 nM), thus conﬁrming the resistance pheno-
type (Gassel et al., 2014). These data suggest that sarolaner binds
at GABACls in a differential manner to cyclodienes and is not neg-
atively impacted by the dieldrin resistance mutation.
Direct comparisons of the receptor pharmacology of sarolaner
to other isoxazolines are made difﬁcult by the different receptor
expression systems and pharmacological methods employed in the
literature. For instance, while ﬂuralaner inhibitory activity at GABA-
Cls was demonstrated using similar recombinant cell lines as the
current study (Gassel et al., 2014), IC50s (<10 nM)  were generated
using a membrane potential ﬂuorescence assay which is an indirect
measure of channel depolarization compared with voltage-clamp
electrophysiology. Moreover, afoxolaner was evaluated against
the Drosophila RDL (IC50 = 3.7 nM), using oocyte expression sys-
tems rather than recombinant cell lines expressing ﬂea and tick
channels (Shoop et al., 2014). For a direct comparison, afoxolaner
inhibitory potency was  investigated using the currently described
methodologies in a side-by side voltage-clamp experiment with
sarolaner. Afoxolaner yielded IC50 values of 539 nM and 412 nM at
CfRDL-A285 and CfRDL-S285 receptors, respectively, which were
signiﬁcantly weaker than the reported inhibition of Drosophila RDL
in the literature (Shoop et al., 2014). Moreover, sarolaner produced
IC50 values that were signiﬁcantly more potent (P < 0.001) than
afoxolaner at both CfRDL-A285 and CfRDL-S285 receptors, thus
highlighting the importance of comparing compounds using the
same receptor expression systems and pharmacological methods.
In an initial exploratory in vivo study in dogs, sarolaner demon-
strated robust efﬁcacy (≥99.8%) for 35 days against both ﬂeas (C.
felis) and adult ticks (R. sanguineus/D. reticulatus)  when delivered in
an oral solution at 2.5 mg/kg. In a subsequent dose ﬁnding study in
dogs against adult I. ricinus,  sarolaner demonstrated very high efﬁ-
cacy (>99.5%) at the lowest dose tested (1.25 mg/kg) using an oral
suspension formulation. No adverse events associated with treat-
ment were observed for any animal in either of the efﬁcacy studies
in dogs.
Taken collectively these data indicate that sarolaner has the
potential to provide month-long efﬁcacy against ﬂeas and multiple
species of tick via the oral route of administration.
5. Conclusions
Sarolaner, the product of a comprehensive research program to
identify a novel isoxazoline parasiticide speciﬁcally for use in com-
panion animals, demonstrated the in vitro whole organism potency,
the pharmacological and pharmacokinetic attributes, and the tar-
get animal safety and in vivo efﬁcacy proﬁles to warrant progression
as a development candidate for a monthly oral parasiticide product
for dogs.
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